<DOC>
	<DOCNO>NCT01806740</DOCNO>
	<brief_summary>Primary objective : The main objective evaluate value DCE-MRI prediction response patient HCC treatment Sorafenib assess mRECIST .</brief_summary>
	<brief_title>DCE-MRI Using Dotarem® Evaluation Therapeutic Response Sorafenib Patients With Advanced Stage HCC</brief_title>
	<detailed_description>Secondary objective : 1 . To evaluate value percent change DCE-MRI/AFP/DWI baseline follow 1 2 week prediction overall survival , progression-free survival , time progression 2 . To evaluate value baseline DCE-MRI/AFP/DWI prediction overall survival , progression-free survival , time progression .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Gadolinium 1,4,7,10-tetraazacyclododecane-N , N ' , N '' , N '' '-tetraacetate</mesh_term>
	<criteria>1 . Age ≥ 20 year old 2 . Subject diagnose Unresectable HCC ( Child Pugh class A major vascular invasion , extrahapatic metastasis , progression TACE 2 time ) . 3 . Presence mRECIST target lesion ( Lesion classify RECIST measurable lesion ( measure ≥ 1 cm least one dimension ) , Lesion suitable repeat measure , Lesion show intraluminal arterial enhancement contrastenhanced CT MRI ) within liver 4 . Patient plan treat sorafenib 5 . Patient liver CT perform plan perform within 4 week initiation Sorafenib treatment 6 . Patient life expectancy 12 week 7 . No previous treatment Sorafenib 8 . Subjects able understand provide write informed consent participate trial . 9 . Female subject surgically sterilize , postmenopausal ( minimum 12 month amenorrhea ) document negative urine hCG test screen 1 . Contraindication MRI ( e.g . : severe claustrophobia , pacemaker , metalic joint replacement accord image center 's standard practice ) 2 . Subjects present know severe renal failure ( estimate creatinine clearance &lt; 30 ml/min calculate CockcroftGault formula estimate GFR &lt; 30ml/min/1.73m² MDRD ) 3 . History hypersensitivity reaction gadolinium contrast medium 4 . Female child bear potential without contraception use least 2 different method 5 . Breast feed pregnant female 6 . Any condition , base investigator 's clinical judgment , would prevent patient complete trial assessment visit ( example : mental physical incapacity , language comprehension , geographical localisation , etc… ) 7 . Previous therapy target lesion within 30 day 8 . Previous radiation therapy target lesion 9 . Subjects participate investigational drug study within 30 day prior study inclusion currently participate another clinical trial involve Investigational Medicinal Product ( IMP ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DCE-MRI</keyword>
	<keyword>Sorafenib response</keyword>
</DOC>